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Abstract 
The circulation of poor-quality medicines continues to undermine the fight against many life-threatening diseases. 
Anti-malarial medicines appear to have been particularly compromised and present a major public health threat in 
malaria-endemic countries, negatively affecting individuals and their communities. Concerted collaborative efforts 
are required from global, regional and national organizations, involving the public and private sectors, to address the 
problem. While many initiatives are underway, a number of unmet needs deserve urgent and increased multisector 
attention. At the global level, there is a need for an international public health legal framework or treaty on poor-qual-
ity medicines, with statutes suitable for integration into national laws. In addition, increased international efforts are 
required to strengthen the governance of global supply chains and enhance cooperation between national medicine 
regulation authorities and law enforcement bodies. Increased investment is needed in innovative technologies that 
will enable healthcare teams to detect poor-quality medicines at all levels of the supply chain. At the regional level, a 
number of initiatives would be beneficial—key areas are standardization, simplification, and reciprocal recognition of 
registration processes and development of quality control capacity in regional centres of excellence that are better 
aligned with public health needs; improved surveillance methods and creation of a framework for compulsory and 
transparent reporting of poor-quality medicines; additional support for national medicine regulation authorities and 
other national partner authorities; and an increase in support for regional laboratories to boost their capabilities in 
detecting poor-quality medicines. It is vital that all stakeholders involved in efforts against poor-quality anti-malarial 
medicines extend and strengthen their actions in these critical areas and thus effectively support global health devel-
opment and malaria elimination programmes.
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Background
In 2015, an estimated 214 million malaria cases occurred 
globally, causing approximately 440,000 deaths [1]. 
Nearly half the world’s population lives in areas where 
malaria transmission is a threat [2]. Although global 
malaria incidence declined by 37  % between 2000 and 
2015, major obstacles remain [1]. Some of these chal-
lenges are anti-malarial and insecticide resistance, lack of 
sustainable funding and poor-quality medicines, which 
could prevent further progress or compromise gains in 
global malaria control.
The circulation of poor-quality medicines, namely fal-
sified (i.e., intentional fraudulent manufacturing) or sub-
standard (i.e., unintentional errors in manufacturing or 
degradation because of poor storage/handling) products 
is a significant barrier to the treatment of many condi-
tions and diseases [3, 4]. Anti-infectives, particularly 
anti-malarials, are vulnerable targets and among the most 
common classes of drugs associated with quality con-
cerns [5–10]. Such medicines pose a major public health 
threat in all endemic countries by simultaneously impact-
ing at multiple levels within a population, affecting indi-
viduals and communities. At the individual level, they can 
cause treatment failures with prolonged or more severe 
sickness and death. In 2013 alone, the consumption of 
poor-quality anti-malarial medicines was estimated to 
have caused over 120,000 deaths among children younger 
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than 5 years in 39 countries in sub-Saharan Africa [11]. 
There can also be financial implications for vulnerable 
patients and families, including loss of income and wast-
age of out-of-pocket expenses. At the public health level, 
by delivering sub-therapeutic drug concentrations, poor-
quality medicines may drive the selection of drug resist-
ance [7, 12, 13]. Furthermore, studies in malaria have 
shown that patients treated with poor-quality anti-malar-
ials have a higher prevalence of gametocytes (sexual-
stage parasites that can transmit from the human host 
back to the mosquito) post-treatment and, therefore, 
there is a higher chance of transmission by mosquitoes of 
drug-resistant parasites to susceptible populations [14]. 
Ineffective treatment translates as depletion of health-
care resources and could result in a loss of public confi-
dence in drugs, pharmacies, and healthcare providers [9]. 
It also threatens confidence in anti-malarial programmes 
at a national and even global level, jeopardizing progress 
and future investment in malaria control and elimination 
[15]. Use of poor-quality medicines in clinical trials is a 
further important concern, as this may compromise the 
reputation of and confidence in effective drugs, health-
care providers, and delivery systems and misinform pub-
lic policy [16].
In 2011, the World Health Organization (WHO) pub-
lished evidence of a substantial problem in the quality of 
anti-malarial products in sub-Saharan Africa [17]. Fur-
ther reports from Africa and Southeast Asia have led to 
international concern and prompted action [3, 5, 7, 8, 15, 
18]. This paper discusses the current evidence base of the 
extent of the problem of poor-quality anti-malarial medi-
cines, the underlying factors, and the feasible actions to 
address this key problem.
Defining and quantifying the problem
Coordinated international actions to address the prob-
lem of poor-quality anti-malarials are hindered by (1) 
the paucity of accessible and reliable information on the 
prevalence of such medicines in circulation, and (2) the 
difficulty this creates in determining their real impact on 
public health. The lack of internationally accepted defini-
tions makes the evaluation of the impact of their circula-
tion even more complex.
Definitions
National and international authorities use an array of 
terms relating to medicine quality, and differences exist 
in the definitions used [7]. The WHO has used the term 
‘substandard, spurious, falsely labelled, falsified and coun-
terfeit’ (SSFFC) to encompass the range of poor-quality 
medicines [19]. However, it is important to differentiate 
between the different forms and levels. In recent years, 
attention has focused on the key distinction between 
‘falsified’ and ‘substandard’ medicines [3, 7, 18]. A ‘falsi-
fied’ medicine is deliberately and fraudulently mislabelled 
with regard to its identity or source (i.e., with criminal 
intent) [20]. Falsification can apply to both branded and 
generic products and refer to medicines in which the 
active pharmaceutical ingredients (API) could theoreti-
cally be correct, wrong, insufficient, or absent, or be a 
result of fake packaging. This definition of falsification 
can also apply to the term ‘counterfeit’. However, this term 
has been primarily associated with intellectual property 
and trademark protection, rather than public health and 
health outcomes, the prime consideration when defining 
the quality of medicines [5]. A ‘substandard’ medicine is a 
genuine drug product that does not meet quality specifi-
cations because of manufacturing error or that degrades 
over time within the recommended shelf-life [18, 20]. The 
specifications typically include a defined content of the 
API and/or the formulation.
Prevalence of poor‑quality anti‑malarial medicines
Estimates of the prevalence of poor-quality medicines 
vary according to the sampling and analytical methods 
used, and reliable, comparable data are sparse [8, 15]. In 
2008, the WHO coordinated a survey of the quality of 
artemisinin-based combination therapy (ACT) and sul-
fadoxine/pyrimethamine medicines in six sub-Saharan 
African countries that had received WHO support to 
strengthen regulatory controls [17]. Overall, 76 of 267 
samples (28.5  %) failed to comply with WHO specifica-
tions. Extreme deviations from the specifications, likely 
to be associated with negative health outcomes, were 
found in 11.6  % of samples. In 2009, a parallel study of 
197 samples was conducted collaboratively by the WHO 
and the United States Pharmacopeia Drug Quality and 
Information Program, in which 44  % of samples from 
Senegal failed quality control tests, along with 30 % from 
Madagascar and 26 % from Uganda [21].
The WorldWide Anti-malarial Resistance Network 
(WWARN) Anti-malarial Quality Literature Surveyor 
[22], an open-access database of published surveys and 
reports, aims to contribute to the understanding of the 
evidence base and clarify how existing data can inform 
relevant public health policies [8]. According to a system-
atic review of 251 studies in the database (1946–2013), 
2813 of 9348 (30.1  %) sampled anti-malarial products 
failed chemical or packaging quality tests: 1107 (39.3 %) 
were classified as falsified, 66 (2.3  %) as substandard, 
and 1640 (58.3 %) as unspecified poor-quality (i.e., with-
out evidence for further categorization) [8]. No publicly 
available reports on the quality of anti-malarial medicines 
were found for 63 of the 104 (60.6  %) malaria-endemic 
countries, and important weaknesses and inconsistencies 
were also evident in study methods and reporting.
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Several recently published large surveys [23–25] and 
reports on drug seizures in Africa and Southeast Asia [16, 
26] warrant continued concern with regard to the preva-
lence of substandard medicines that fail tests of API con-
tent (Table 1). Some surveys conducted between February 
2010 and February 2013 have also found artesunate mono-
therapy tablets in circulation in sub-Saharan Africa [23, 27, 
28] and Southeast Asia [26]. This may be partly due to the 
difference in expense, as the total cost of ACT is approxi-
mately double that of monotherapy. Additionally, analysis 
suggests that monotherapy is used mainly in self-treatment 
by adults purchasing from patent medicine vendors, which 
indicates the need to continue and extend public aware-
ness of ACT [29]. Recent reports suggest such campaigns 
have been relatively successful in Cambodia [30] and Lao 
People’s Democratic Republic (Laos) [31] as the use of 
artemisinin monotherapy has become less common fol-
lowing its global ban in 2006 [32]. Political awareness has 
also increased and specific actions have been carried out 
related to artemisinin resistance emergence in this region.
Multi‑level factors and consequences
The circumstances that enable the manufacture and cir-
culation of poor-quality medicines are multifactorial and 
are often inter-linked, impacting at the global, national, 
population, and individual levels (Fig. 1).
Global
  • Lack of effective surveillance the absence of a global 
system for the mandatory reporting, assessment, and 
Table 1 Summary of selected recently published surveys of anti‑malarial medicines quality in Africa and Southeast Asia
a Samples included amoxicillin, artemether/lumefantrine powder for suspension in paediatric dosage and paracetamol tablets 500 mg
Region/country and year Product and number 
of samples
Source(s) and sampling Key results
Africa
 Tanzania
 2010
 [24]
Artemisinin-containing
N = 1737
Source: private retail outlets
Sampling: nationally representative 
sample
All samples contained an API
Artemisinin-containing derivative:
4.1 % substandard (outside the 85–115 % API range)
PQ drugs had 10 % of the odds of being poor-
quality vs non-PQ
Partner drugs
12.1 % substandard
PQ had 4 % of the odds of being poor-quality
 Ghana, Togo
 2010–2011
 [28]
Artemisinin-containing
N = 132
Source: retail outlet
Sampling: convenience sample
Only one sample lacked an API
Combination products: 83.7 % (outside 90–110 % 
API)
Monotherapy: 57.9 % substandard
 Nigeria
 2012–2013
 [23]
Artemisinin-containing
N = 3024
Sources: pharmacies (35.6 %), patent 
medicine vendors (60.6 %), public 
health facilities (3.6 %), market stalls 
(0.2 %)
Sampling: mostly mystery client 
(63.5 %), then overt (6.6 %) or con-
venience (29.9 %)
9.2 % poor-quality: 6.8 % substandard; 1.3 % 
degraded; 1.2 % falsified
Convenience sampling yielded a significantly higher 
prevalence of poor-quality
 Democratic Republic of 
Congo
 2014
 [25]
Artemisinin-containing
N = 238a
Source: private licenced wholesalers
Sampling: cross-sectional, mystery 
client
21 % were found non-conform for the content in API
48 % were under-dosed in artemether
Southeast Asia
 Cambodia
 2010–2011
 [30]
Artemisinin derivatives
N = 291
Sources: private health provider
Sampling: mystery client
All samples contained an API
Overall: 31.3 % substandard (outside range of 85 % 
and < 115 %)
24.7 % were expired
Artesunate tablets: 25.8 % (60/233) substandard
Co-blistered mefloquine: 73.4 % (149/203) substand-
ard
Considering both drugs: 77.3 % (157/203) substand-
ard
 Lao People’s Democratic 
Republic (Laos)
 2012
 [31]
Various anti-malarial 
medicines
N = 146
Source: Private retail outlets
Sampling: Cross-sectional random 
sample, mystery client
All samples contained an API
25.4 % substandard (outside 90–110 % API)
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dissemination of information on falsified and sub-
standard medicines is a major obstacle to measuring 
the scale of the problem, raising sufficient aware-
ness, and improving global medicines supply [33]. 
This problem is amplified by deficits in national-level 
quality surveillance in many malaria-endemic coun-
tries [34].
  • International supply chain regulation the globalized 
marketplace means that medical products can be 
manufactured in one country, packaged in another, 
and supplied to others with limited international 
oversight of manufacturing, testing, or storage prac-
tices for legitimate medicines or the introduction of 
deliberately falsified products into the supply chain 
[7].
  • Legal insufficient legal action against falsified and 
substandard (if negligence could have been cor-
rected) medicines are facilitated by inadequate and/
Inadequate  
national medicines 
regulation 
DEMAND 
Limited access to  
affordable, high-quality 
medicines 
• Inadequate international legal definitions & 
framework covering poor-quality medicines 
• Economic constraints 
• Political will/prioritization 
Vendors/ 
suppliers 
Inadequate 
criminal law &  
law enforcement 
Inadequate  
surveillance 
Inadequate 
manufacturing 
standards 
Inadequate 
quality 
assurance 
Legitimate  
manufacturers 
Fraudulent 
manufacturers 
Substandard  
medicines 
Falsified  
medicines 
Patients Limited public  awareness 
Antimalarial 
resistance 
Treatment failure: 
extended disease, death 
Threat to confidence in 
health providers, 
systems & programmes  
Fig. 1 Key factors in the manufacture and circulation of poor-quality antimalarial medicines: targets for action
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or unharmonized international and national laws and 
law enforcement against this form of fraud. The regu-
lation of legitimate medicines manufacture is also 
hampered by the lack of a consistent legal framework 
[35].
National
  • National regulation the weakness of national medi-
cine regulation authorities (NMRAs) in many coun-
tries is a central concern with regard to both falsified 
and substandard medicines. Documented short-
falls in national regulation in developing countries 
include: low prioritization of regulation within health 
systems; fragmentary, out-dated, and poorly coor-
dinated regulatory frameworks; uneven and weak 
implementation of functions; inadequate adaptation 
and use of guidelines; inappropriate organizational 
structures (not able to ensure transparency, inde-
pendence, and accountability); weak inter-sectoral 
collaboration nationally and among countries; short-
ages of qualified staff; and inadequate and unsustain-
able funding [34, 36].
  • Access to good-quality medicines limitations on 
access to affordable good-quality treatment can drive 
demand for poor-quality medicines, or for mono-
therapy. A shortage of medicines can also lead to a 
reliance on unknown suppliers and illicit/uncon-
trolled supply chains, where the risk of poor-quality 
medicines may be greater. The introduction of falsi-
fied meningococcal vaccines during the 2015 out-
break in Niger illustrates the rapid capability of this 
organized crime [37].
  • Costs of testing for medicine quality standard methods 
of testing drug reliability, such as high-performance 
liquid chromatography and spectroscopy, require 
high-cost instruments, expensive maintenance, and 
trained proficient staff. These constraints, in addition 
to less-than-optimal operational conditions, inhibit 
the use of these techniques in low-income malaria-
endemic countries [38]. Development of portable 
rapid-testing methods, which are discussed in more 
detail in the surveillance and quality testing section 
below, offer the prospect of introducing less expen-
sive and more sensitive technologies. However, the 
absence of a single affordable, reliable, validated, and 
portable technology currently remains a barrier [39].
Population and individual 
  • Anti-malarial resistance sub-therapeutic drug con-
centrations may facilitate the selection and spread of 
anti-malarial drug resistance [7, 12, 13, 40].
  • Public confidence ineffective treatments can result in 
a loss of public confidence in drugs, pharmacies, and 
healthcare providers, as well as in anti-malarial pro-
grammes [15].
  • Public awareness evidence suggests that levels of 
public awareness about poor-quality medicines in 
malaria-endemic areas are sub-optimal [41]. This is 
particularly important given the frequency of self-
medication.
  • Treatment failure inadequate therapy leads to 
extended, more severe illness, and increased fatalities 
compared with recommended therapy [11].
  • Financial loss of income and increased expenses for 
patients and families.
The success of malaria treatment has not gone unno-
ticed by criminal elements that desire to profit from this 
accomplishment by manufacturing falsified anti-malar-
ials. Multisector collaboration involving bodies at the 
international and national levels is needed to address 
this and other factors that drive and facilitate the manu-
facture and dissemination of falsified and substandard 
medicines. These bodies include the WHO, non-gov-
ernmental organizations, the scientific community, 
national governments, NMRAs, law-makers and law 
enforcement authorities (including police, customs, and 
the International Criminal Police Organization [INTER-
POL]), public health bodies, healthcare providers, civil 
society, and pharmaceutical manufacturers. The follow-
ing sections discuss actions underway to improve qual-
ity standards.
Improving quality standards
Surveillance and quality testing
Surveillance is fundamental to the planning and imple-
mentation of national malaria programmes [42]. 
Enhanced pharmacovigilance is needed to monitor the 
safety and efficacy of anti-malarial medicines and man-
age anti-malarial drug resistance, to ensure that the most 
appropriate combinations are used [42]. Currently, the 
quality and comprehensiveness of surveillance data on 
medicines quality are limited, mainly because of: the lack 
of a consensus in malaria-endemic countries on regula-
tions for surveillance definitions and methods; the vol-
untary status of reporting requirements; and inadequate 
training, equipment, and funding at the level of NMRAs.
At present, specific efforts to improve surveillance 
are focused on survey approaches, methods linked to 
information sharing systems, and new analytic tech-
nologies. The WHO is developing new policies on 
sampling procedures and reporting medicine quality 
surveys. Draft recommendations [43] and guidelines 
[44] are in preparation to help improve monitoring and 
post-market surveillance. The WHO Medical Product 
Alert system is an important vehicle for NMRAs and 
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other bodies to share information regarding incidents 
involving poor-quality medicines [45]. This reporting 
system started in 2013 and has received approximately 
1000 reports since its launch. However, as the alerts 
issued by The WHO Medical Product Alert system 
are voluntary, sporadic, and not always public, it has 
been proposed that these alerts are made mandatory 
and included in international health regulations [33]. 
Timely reporting would facilitate corrective actions 
appropriate to the event described. The WWARN Anti-
malarial Quality Literature Surveyor allows users to 
track and evaluate the evolving evidence base of anti-
malarial medicine quality via customizable maps and 
tables [22]. Extending the classes of medicines included 
in surveillance programmes may broaden the interest 
of potential sites.
Pharmaceutical companies also have a role in reporting 
any suspected poor-quality medicine, with internal poli-
cies covering verification processes and timely engage-
ment with relevant national and global stakeholders. The 
2016 Access to Medicine Index emphasizes the need for 
all pharmaceutical companies to have such policies [46]. 
Mackey et  al. described 1510 Pharmaceutical Security 
Institute Counterfeit Incident System reports from 2009 
to 2011 involving global legitimate medicine supply chain 
penetration [10]. This information was collected by the 
Pharmaceutical Security Institute, a not-for-profit mem-
bership organization of 33 pharmaceutical manufacturers 
[47].
The development of novel analytic technologies offers 
promise in facilitating surveillance and identification of 
suspect drugs at point-of-care by drug inspectors and 
law enforcement officials. Examples include Raman 
spectroscopy [38, 48, 49], the US Food and Drug Admin-
istration-supported counterfeit detection device (CD-3) 
[31, 38, 50, 51], the counterfeit drug indicator (CoDI) 
[38], new colorimetric assays [38], chemical colour test 
cards [52], and track-and-trace packaging design [53]. 
However, these are not yet widely affordable nor read-
ily scalable, and further work is required to validate their 
use and performance in tropical contexts for anti-malar-
ial medicines and to define their role in practice at differ-
ent levels of the supply chain [3]. Ultimately, such tools 
can only be effective if placed in the hands of adequately 
resourced and trained public health staff who could 
report to NMRAs.
Furthermore, quality failure rates can vary owing to a 
lack of harmonization or agreed-upon detection stand-
ards (i.e., standardization), and criminal producers of 
falsified medications may adapt their formulations in an 
attempt to fool less-rigorous tests [54]. Therefore, sus-
pect products may require full analysis at NMRA-certi-
fied laboratories for comprehensive investigation.
The WHO prequalification of medicines programme
The WHO prequalification of medicines programme 
aims to increase the availability of quality-assured priority 
medicines through evaluation and inspection activities, 
and by building national capacity for high-quality manu-
facturing and monitoring [55]. Currently, this is the only 
global medicines quality assurance programme and, in 
addition to medicinal products, it also prequalifies APIs 
and quality control laboratories. The prequalification 
programme has many benefits to pharmaceutical manu-
facturers, including participation in international tenders, 
facilitated registration in some recipient countries, capac-
ity building, technical assistance, and the benefits con-
ferred by credibility among procurement and NMRAs.
This programme is conducted in cooperation with 
NMRAs. Onsite inspections are made to ensure the 
manufacturing site and any associated contract research 
organizations are compliant with WHO standards. Data 
from a 2008 survey support the effectiveness of the pro-
gramme. Only 3 of 83 (3.6  %) tested prequalified medi-
cines were found to be non-compliant with standards, 
compared with 29 of 48 (60.4 %) non-prequalified prod-
ucts [6]. Prequalified artemisinin-containing medicines 
were recently found to have 10  % of the odds of being 
poor-quality compared with non-prequalified medi-
cines (Table 1) [24]. Lack of sustainable funding is a con-
tinuous challenge for this effective programme [56]. The 
WHO prequalification is a lengthy process and limited 
resources have impaired its ability to support a larger 
number of manufacturers; extend the range of medicines 
beyond that of HIV/AIDS, malaria, tuberculosis, and 
reproductive health; or be responsive to prequalification 
requests in a timely manner. Currently, the prequalifica-
tion process takes a minimum of 3  months from appli-
cation to approval (if the product meets all the required 
standards) [57].
A corresponding process is used to prequalify qual-
ity control laboratories [17], although responsibility for 
formal approval of laboratories rests with NMRAs. The 
WHO invites NMRAs to observe on-site inspections and 
notifies NMRAs when laboratories achieve prequalifi-
cation. The main limitation of this initiative is the small 
number of prequalified laboratories: currently there are 
40, of which 21 are in malaria-endemic countries and 
only seven exist in five countries in sub-Saharan Africa 
(Fig. 2) [58]. Localization of these qualification processes 
should be the long-term goal, and funding should be 
made available so that the precertification and qualifica-
tion processes can occur within each country.
Other initiatives
There are many initiatives that aim to support the global 
use of quality medicines, and comprehensively detailing 
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each of these would be beyond the scope of this paper. 
However, some key examples are described.
The WWARN quality assurance/quality control pro-
gramme has been initiated and has assumed a leader-
ship position in helping local laboratories to assess and 
improve their assay quality [59–61]. This programme has 
two major components: a proficiency testing programme 
and a reference material programme.
The ACT consortium has four key research themes, 
one of which is quality. It states that the impact of 
improved delivery of ACT will be undermined if the 
drugs are of suspect quality owing to counterfeiting, sub-
standard manufacturing, or degradation from poor or 
prolonged storage [62].
The ‘Promoting the Quality of Medicines in Developing 
Countries’ (PQM) programme is a United States Phar-
macopeial Convention (USP) and United States Agency 
for International Development (USAID) partnership 
that helps developing countries address critical issues 
related to poor-quality medicines [63]. Through an array 
of activities, including medicine quality monitoring, edu-
cation campaigns, and assistance in legislation and regu-
lations [64], the PQM programme strives to accomplish 
four key objectives: to strengthen quality assurance and 
quality control systems; increase the supply of quality-
assured medicines; combat the availability of substandard 
and counterfeit medicines; and provide technical leader-
ship and global advocacy [63].
There are several other programmes launched by the 
USP, including the Regulatory Standards Assistance Pro-
gram, which provides developing countries with tools to 
increase their capacity to test the quality of medicines for 
their citizens. In 2011, the Regulatory Standards Assis-
tance Program began with five countries in Africa; it 
has since expanded to include more than 35 countries in 
Africa, Asia, and Latin America and the Caribbean. This 
programme provides participating countries with a pack-
age of reference standards selected by the participating 
country from the USP’s catalogue, documentary stand-
ards, and analytical data to test medicines to strengthen 
the reliability of quality control tests.
The Global Fund is a financing institution that supports 
programmes run by local experts against HIV/AIDS, 
tuberculosis, and malaria. Global Fund grants may only 
be used to procure pharmaceutical products in accord-
ance with the standards prescribed in the Global Fund 
quality assurance policy. One of these standards requires 
anti-malarials to be prequalified by the WHO Prequali-
fication Programme or authorized for use by a Stringent 
Drug Regulatory Authority [65, 66].
Health policy issues
National registration process
Effective regulation to ensure the quality of anti-malar-
ial medicines being manufactured, imported, and sup-
plied within a country is fundamental to prevent the 
Mexico: 1a 
Canada: 1 
Brazil: 2a 
Morocco: 1 
Algeria: 1a 
South Africa: 2a 
China: 1a 
Bolivia: 1a 
Peru: 1a 
Singapore: 1 
Vietnam: 1a 
Thailand: 1 
India: 4a 
Pakistan: 1a 
Russia: 2 
Zimbabwe: 1a 
Tanzania: 1a 
Kenya: 2a 
Uganda: 1a 
Portugal: 2 
France: 1 
Germany: 1 
Ukraine: 3 
Belarus: 1 
Belgium: 2 
Switzerland: 1 
The Netherlands: 2 
Uruguay: 1 
Americas: 7 
African region: 8 
European region: 15 
Eastern Mediterranean: 2 
Western Pacific: 3 
Southeast Asia: 5 
Fig. 2 Map showing the locations of prequalified quality control laboratories [56]. aCountries with endemic malaria (ongoing) [1]
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circulation of falsified and substandard medicines. As part 
of its Global Malaria Strategy, the WHO recently urged all 
NMRAs in endemic regions to remove all inappropriate 
and ineffective anti-malarial medicines from healthcare 
facilities, pharmacies, informal providers, and private sec-
tor markets. NMRAs are also urged to regulate against the 
production, marketing authorization, export, import, and 
use of oral artemisinin-based monotherapies [42].
The WHO has specifically highlighted the need to rap-
idly build greater regulatory capacity in African countries, 
in terms of management structures, technical expertise, 
inter-country harmonization, and collaboration, as well 
as physical resources [34, 36]. The obstacles to progress in 
regulatory control have been well summarized and a series 
of actions have been proposed (Table 2) [36]. The regional 
strategy on regulation of medical products in the African 
region will be reviewed at the 66th session of the WHO 
Regional Committee for Africa (Addis Ababa, Federal 
Republic of Ethiopia, 27–30 August 2016). The WHO Pre-
qualification of Medicines Programme supports NMRAs to 
improve manufacturing standards for legitimate medicines, 
providing training and tools, as well as via the prequalifica-
tion certification itself. However, considerable expansion of 
the laboratory prequalification programme is clearly needed 
in malaria-endemic areas (Fig. 2). The US Institute of Medi-
cine recommended that international funding should be 
made available to assist pharmaceutical manufacturers who 
wish to upgrade to international standards [7].
National Medicines Regulatory Authorities (NMRAs) 
and World Health Organization (WHO)
Weak international collaboration and harmoniza-
tion between NMRAs (e.g., for mutual recognition of 
marketing authorizations) has been identified by WHO 
as a problem, especially in Africa (Table 3) [36]. Surveyed 
pharmaceutical companies have indicated that varying 
national regulatory requirements are a barrier to reg-
istering and supplying medicines to African countries 
[67]. More than 50 local NMRAs are working indepen-
dently across Africa to register medicines with different 
administrative and technical requirements, different reg-
istration processes, and limited transparency during the 
process [68]. Efforts toward regulatory harmonization 
are underway in Africa under the auspices of the African 
Medicines Regulatory Harmonization Programme—a 
consortium of partners including the WHO, Pan-African 
Parliament, New Partnership for Africa’s Development, 
the UK Department for International Development, 
the Clinton Foundation, and the Bill and Melinda Gates 
Foundation. Major stakeholders are NMRA representa-
tives, the European & Developing Countries Clinical 
Trials Partnership, the Deutsche Gesellschaft für Inter-
nationale Zusammenarbeit, the European Medicines 
Agency, the International Federation of Pharmaceutical 
Manufacturers & Associations, and the African Regula-
tory Network. The African Medicines Regulatory Har-
monization initiative aims to establish five to six regional 
groups (each with harmonized technical requirements) 
that will coordinate registration processes across the 
African continent. The regional groups will have stand-
ardized processes and documentation, as well as stream-
lined, faster, and more-reliable processes that are better 
aligned with the public health needs of each regional 
group. Progress has been made, especially in East Africa, 
with the WHO/East African Community (EAC) Medi-
cines Regulatory Harmonization project (Burundi, 
Kenya, Tanzania, Uganda, Rwanda, and Zanzibar): four 
joint assessment sessions in 9  months have resulted in 
approvals in EAC NMRAs less than 2 months after joint 
acceptances by the EAC/WHO. Actions on regulatory 
harmonization are also underway in Southeast Asia via 
the Pharmaceutical Product Working Group of the Asso-
ciation of Southeast Asian Nations Consultative Com-
mittee for Standards and Quality and in the Asia–Pacific 
Economic Co-operation region via the Asia Pacific Har-
monization Center [69, 70].
Enforcement of drug regulations is another area in 
which collaboration is essential. National-level action 
against deliberately falsified medicines requires NMRAs 
to conduct collaborative investigations with police and 
customs. Operation Storm I and II, conducted in 2008 
and 2009 in Cambodia, Indonesia, Laos, Myanmar, Sin-
gapore, Thailand, and Vietnam, offered an example of 
this sort of multisector collaboration. Coordinated by 
WHO and INTERPOL, these operations involved a syn-
ergistic partnership between customs authorities, police, 
Table 2 Actions proposed by  the WHO Regional Commit‑
tee for Africa [36]
a Defined as NMRAs, manufacturers, traders, consumers and other 
representatives of civil society, health professionals, researchers, police, customs, 
the judiciary, governments, and parliamentarians
Prioritize the development of medical products regulation
Strengthen the coherence and performance of the medicines regulatory 
system (including dialogue among stakeholders)a
Adapt and use guidelines in line with WHO recommendations
Increase implementation of regulatory functions
Enhance the status of NMRAs
Institute sustainable mechanisms to effectively manage conflicts of 
interest
Strengthen inter-sectoral collaboration between relevant stakeholders
Ensure availability of qualified human resources for regulation of medical 
products
Ensure adequate and sustainable financing of the medicines regulatory 
system
Improve collaboration, coordination, and harmonization of medical 
products regulation
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NMRAs, and laboratories in participating countries [26]. 
Encouraging data from Cambodia suggest that measures 
to strengthen drug regulation and enforcement capac-
ity and improve education and communication have 
reduced the circulation of falsified anti-malarial prod-
ucts, although substandard medicines remain common 
and are a specific threat for resistance [30].
The Global Fund has established a Joint Interagency Task 
Force (JIATF) to pro-actively engage with NMRAs and 
law enforcement authorities, and to provide information 
on the circulation of falsified medicines (based on its own 
data gathering and analysis), training, and analytic tech-
nologies [72]. Supporting NMRAs has also been defined as 
a priority for attention by the Global Steering Committee 
for the quality assurance of health products [72].
Legal aspects
Action is needed at both the international and national 
levels to strengthen laws and law enforcement with regard 
to both falsified and substandard medicines. There have 
been calls for an international treaty, founded on consid-
erations of public health (rather than intellectual prop-
erty), to define and differentiate in law the different forms 
of poor-quality medicines, provide a framework for crimi-
nal prosecution (commensurate with the relative serious-
ness of the offences and intentions of the perpetrator), 
and harmonize regulatory standards [3, 18]. The 2013 
protocol to eliminate the illicit trade in tobacco products 
within the Framework Convention on Tobacco Control 
[73] has been cited as a suitable model for this treaty.
At the national level, Attaran [35, 74] recently pro-
posed a Model Law on Medicine Crime as a flexible 
template for any country to use to strengthen relevant 
laws on poor-quality medicines. This Model Law is con-
sistent with the principles above and also has provisions 
concerning internet ‘pharmacies’, ‘whistle-blowers’, and 
unregistered medicines.
Access, finance, and political commitment
In 2013, the United Nations urged all states to estab-
lish national health and regulatory infrastructures and 
domestic management capacities to ensure that all citi-
zens have access to medicines that are affordable, safe, 
efficacious, and of good-quality, and for the international 
community to continue to assist in achieving this goal 
[75]. The WHO’s current global malaria strategy empha-
sizes the importance of providing universal access to 
quality-assured and appropriate anti-malarial medicines 
(together with diagnostics and vector control measures) 
as the first priority for countries with high or moderate 
malaria transmission rates [42]. This strategy needs to 
be extended into areas of low- and unstable transmis-
sion given that individuals in these settings have little 
acquired immunity and are more likely to suffer from 
severe malarial disease; furthermore, these environ-
ments are probable sources of drug-resistant parasites 
[76, 77]. Provision of good-quality medicines via public 
and private sector health services is important to prevent 
patients from turning to unreliable private sources [20]. 
Political commitment and financing is, therefore, vital 
to ensure that good-quality medicines are available and 
affordable [42].
Call to action
Access to good-quality medicines is an essential human 
right and a top priority in the global fight against many 
life-threatening diseases including malaria [42]. The 
continued circulation of poor-quality (falsified and sub-
standard) medicines in endemic regions is a key threat to 
future progress and public health as a whole. Although 
many actions are underway, important unmet needs 
remain and these warrant urgent attention and concerted 
multisector action, led and coordinated by a globally 
mandated organization at the international and national 
levels.
Table 3 How can the medicine registration processes in Africa be improved?
Source: The New Partnership for Africa’s Development (NEPAD) and the World Health Organization (WHO). African Medicines Registration Harmonisation Initiative: 
Summary, Status and Future Plans [71]
Today’s current environment A harmonized future environment
~50 different NMRAs (working  independently) to register medicines 
across Africa 
~5 or 6 regional groups (each with  harmonized technical requirements) coordi-
nating registration across the entire  African continent
Different administrative and technical  requirements, processes, and 
procedures for  medicines registration across NMRAs
Common (harmonized) registration documentation (format and technical  
requirements),  procedures, and decision-making processes across African 
regional groups
No clear indication of the time taken, or the  maximum  times  
allowed, for regulators to  assess and register medicines
Streamlined processes that are faster, more  predictable, and better aligned to 
public health needs (in terms of prioritization, conditional approvals, etc.)
Limited transparency before or during the registration process Transparent and clear procedures and a good understanding of registration  
requirements and processes by all stakeholders
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Given the current situation, urgent action is required 
by the international community across eight key areas:
1. Confer sustained international and national political 
commitment and financing to drive these and other 
measures necessary to ensure access to quality medi-
cines and thereby protect public health.
2. Form a more comprehensive international, pub-
lic health-orientated legal framework or treaty on 
poor-quality medicines, with statutes integrated into 
national laws.
3. Provide further international efforts to strengthen 
governance of global medicines supply chains, har-
monize regulatory standards and related procedures, 
and facilitate international cooperation between 
NMRAs and law-enforcement bodies.
4. Develop harmonization of registration processes in 
regional centres of excellence with common registra-
tion documentation, procedures, and decision-mak-
ing procedures that are better aligned with public 
health needs.
5. Nationally, develop NMRAs that are adequately pri-
oritized, resourced, structured, and trained to allow 
them to perform all regulatory functions (including 
systematic surveillance, manufacturing oversight, 
quality assurance, registration, and enforcement) in 
collaboration with the other national partner author-
ities.
6. Invest in innovative technologies globally and nation-
ally to support anti-malarial initiatives, particularly 
the detection of poor-quality medicines at all levels 
of the supply chain, and track-and-trace technologies 
that ensure a valid product from the manufacturing 
facility to the consumer.
7. Arrange specific global and regional support to 
increase the number of prequalified standardized ref-
erence laboratories that can detect poor-quality anti-
malarial medicines and also drive the validation and 
scaling-up of new field technologies for surveillance 
and analysis, particularly in malaria-endemic coun-
tries via appropriate training and resourcing.
8. National and regional surveillance to be linked to 
effective routine and transparent reporting of inci-
dents followed by an immediate withdrawal of prod-
ucts in the case of major findings by national authori-
ties. Reporting of events should be made compulsory 
and a data-sharing policy involving public and pri-
vate sectors, patient representatives, academics, non-
government organizations, and international bodies 
should be developed accordingly.
While it is not the intention of this publication to allocate 
responsibilities to defined organizations and initiatives, 
questions on strategic roles must be discussed and clearly 
assigned for future coherent actions. These eight key areas 
are considered as the priorities for all stakeholders, includ-
ing the scientific and medical community and health poli-
cymakers, and the joint actions of these groups will be 
critical in driving forward effective malaria elimination 
programmes and global health development.
Conclusions
The continued circulation of poor-quality anti-malarial 
medicines poses a significant threat to global advances 
in combating malaria. There are many ongoing initia-
tives designed to address different aspects of the prob-
lem; however, it is imperative that key unmet needs are 
addressed with urgent multisector action. The role of 
the international community is vital in extending and 
strengthening actions across eight crucial areas and rein-
forcing the fight against malaria.
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